

CMX001 therapeutic dosing and the maximum delay in treatment that can afford protection from lethal disease.

doi:10.1016/j.antiviral.2008.01.132

119

Synthesis of P–O–C-linked Foscarnet–Peptide Conjugates and Sensitive Methods to Detect the Released Drug in Biological Samples

Chi V. Pham^{1,*}, Boris A. Kashemirov¹, Jorge Osuna¹, Kanokkarn Saejueng¹, John M. Hilfinger², Charles E. McKenna¹

¹ Department of Chemistry, University of Southern California, Los Angeles, USA; ² TSRL, Inc., Ann Arbor, USA

The trisodium salt of phosphonoformic acid (PFA), foscarnet, is an analogue of pyrophosphate that inhibits a broad spectrum of viruses. A long-recognized limitation of foscarnet has been its very low oral bioavailability, which is due to the ionization of PFA at physiological pH. As a result, in the clinic it can only be administered intravenously. Here, we report the synthesis of a series of novel PFA prodrugs, created by incorporation of toxicologically benign amino acids or small peptides to abate the anionic state of the drug. Previous work done in our laboratory demonstrated the synthesis of P–N linked PFA-amino acid conjugates, which cleanly release the parent drug at physiological pH. In this work, conjugates of PFA monosalts were esterified by the alcohol side-chain group of serine using Mitsunobu chemistry to create the P–O–C link. The detection and analysis of foscarnet is made difficult by its lack of a visible–UV chromophore, therefore we have also sought improved methods to determine the parent drug released from the conjugates. Two new approaches (UV detection via formation of a Yb³⁺/pyrocatechol violet complex, and fluorescence detection by formation of a 9,10-bis[(2,2'-dipicolylamino)methyl] anthracene zinc complex) will be compared with detection using LC–MS/MS.

Acknowledgements

This work was supported by NIH grant U01 AI061457.

doi:10.1016/j.antiviral.2008.01.133

120

In Vivo Efficacy of CMX001 Against Herpes Simplex Virus Types 1 and 2

Debra Quenelle^{1,*}, Deborah Collins¹, Terri Rice¹, George Painter², Alice Robertson², Earl Kern¹

¹ The University of Alabama, School of Medicine, Birmingham, USA; ² Chimerix, Inc., Durham, USA

CMX001, or HDP-cidofovir, has been previously reported to have excellent activity both *in vitro* and *in vivo* against vaccinia virus (VV), cowpox virus (CV) and human cytomegalovirus (HCMV). In the current studies, CMX001 was synthesized as a free acid form instead of the salt forms used previously and evaluated in murine models of herpes encephalitis and neonatal

herpes. Compound was suspended in 0.4% carboxymethylcellulose to yield desired dosages in a 0.2 ml volume. Mice were lethally infected intranasally with herpes simplex virus (HSV), type 1, E-377, MB-1 or HSV-2, strain MS and treatments were delayed until 24 h post viral infection. CMX001 was administered orally once daily at 2.5, 5 or 10 mg/kg beginning 24 h post HSV infection and continued for 7 days. CMX001 exhibited some toxicity at the 10 mg/kg dosages in uninfected and infected mice. Treatment with CMX001 significantly reduced mortality of HSV-1 infected mice at 5 and 2.5 mg/kg doses ($P < 0.001$). Also, CMX001 significantly reduced mortality in HSV-2 infected mice at 5 and 2.5 mg/kg doses ($P < 0.001$). Acyclovir (ACV) was administered twice daily beginning 24 h post HSV infection as a positive control at 30, 60, or 120 mg/kg. ACV was effective in reducing or eliminating mortality at all doses evaluated ($P < 0.001$). In these studies, CMX001 was as efficacious as ACV at non-toxic doses of 5 and 2.5 mg/kg. Additional evaluation of CMX001 will be required in order to assess its potential for the treatment of serious HSV types 1 and 2 infections in humans.

doi:10.1016/j.antiviral.2008.01.134

121

A Synthetic Strategy to Different Cyclopentenyl-Nucleosides

Bastian Reichardt*, Chris Meier

Institute of Organic Chemistry, Department of Chemistry, Faculty of Science, University of Hamburg, Martin-Luther-King-Platz 6, D-20146 Hamburg, Germany

Carbocyclic nucleosides are compounds in which the furan ring has been replaced by a cyclopentane system. They possess increased metabolic stability against nucleoside phosphorylases as well a higher conformational flexibility. In the past, carbocyclic nucleoside analogues like abacavir showed very interesting antiviral properties *in vitro* and *in vivo*. Abacavir was approved as a HIV-drug for clinical application. Therefore, we were interested in a short and efficient stereoselective access to this class of compounds. As starting material 3-benzyloxymethylcyclopent-3-enol was chosen, that can be prepared from cyclopentadiene after deprotonation and alkylation using benzylchloromethylether to give symmetric benzyloxymethylcyclopentadiene. This compound isomerizes into two thermodynamically more stable benzyloxymethylcyclopentadienes. This mixture of compounds material can be used as precursor for the synthesis of different 3',4'-cyclopentenyl-nucleosides. This material can be oxidized to 3-benzyloxymethylcyclopent-3-enone. The β,γ -unsaturated ketone undergoes isomerization into 3-benzyloxymethylcyclopent-2-enone. After reduction, the resulting 3-benzyloxymethylcyclopent-2-enol can be used as precursor for the synthesis of different 4',6'-cyclopentenyl-nucleosides. Moreover, this strategy offers the possibility for the synthesis of new carbocyclic nucleosides because the double bond can be functionalized before or after introduction of the nucleobase. The synthesized carbocyclic nucleosides were converted into their monophosphates by